Richard A Glennon

This inventor holds 13 USPTO granted patents and 1 published patent application and 1 EPO patent. Top assignees: Virginia Commonwealth University, Allelix Biopharmaceuticals Inc., Cambridge Neuroscience, Inc.. Active years: 1996-2004.

USPTO Granted Patents = 13 (Patent Applications = 1)

% Patents Active = 69.2

EPO Patents = 1 (Patent Applications = 1)

Average Co-Inventor Count = 1.4

ph-index = 5

Forward Citations = 265(Granted Patents)

Location History:

Midlothian, VA (US) (2002 - 2003)
Richmond, VA (US) (1996 - 2004)

Company Filing History:

12 out of 420

Virginia Commonwealth University

patents

1 out of 69

Allelix Biopharmaceuticals Inc.

patents

1 out of 43

Cambridge Neuroscience, Inc.

patents

where one patent can have more than one assignee

Years Active: 1996-2004

Loading Chart...

13 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 6806283 - Selective serotonin receptor antagonists and therapeutic applications thereof (2004-10-19),

2. 6518297 - Selective 5-HT6 receptor ligands (2003-02-11),

3. 6489488 - Selective 5-HT6 receptor ligands (2002-12-03),

4. 6403808 - Selective 5-HT6 receptor ligands (2002-06-11),

5. 6288101 - Imidazoles with serotonin receptor binding activity (2001-09-11),

6. 6124338 - Imidazoles with serotonin receptor binding activity (2000-09-26),

7. 6087346 - Sigma receptor ligands and the use thereof (2000-07-11),

8. 6057371 - Sigma receptor ligands and the use thereof (2000-05-02),

9. 6048862 - Benzylamidine derivatives with serotonin receptor binding activity (2000-04-11),

10. 5969137 - Benzylamidine derivatives with serotonin receptor binding activity (1999-10-19),

11. 5919794 - Methods of using pharmaceutical tetrahydroisoquinolines (1999-07-06),

12. 5504101 - 5-HT-1D receptor ligands (1996-04-02),

13. 5496957 - Tryptamine analogs with 5-HT1D selectivity (1996-03-05),

Title: The Innovative Contributions of Richard A. Glennon

Introduction

Richard A. Glennon is a prominent inventor based in Richmond, VA, known for his significant contributions to the field of pharmacology. With a total of 13 patents to his name, Glennon has made remarkable strides in the development of therapeutic agents aimed at treating mental disorders. His work has had a profound impact on the understanding and treatment of conditions such as depression and anxiety.

Latest Patents

Among his latest patents, Glennon has developed selective serotonin receptor antagonists, specifically focusing on compounds such as Spiro[9,10-dihydroanthracene]-9,3'-pyrrolidine (SPAN) and its derivatives. These compounds serve as selective, high-affinity antagonists of 5-HT serotonin receptors, proving useful as antidepressant and antianxiety agents. Additionally, he has identified selective 5-HT6 receptor ligands that exhibit enhanced affinity and selectivity for 5-HT receptors. These compounds hold therapeutic potential for treating mental disorders and can be utilized in screening methodologies to identify further antagonists of 5-HT receptors.

Career Highlights

Glennon's career has been marked by his association with esteemed institutions such as Virginia Commonwealth University and Cambridge Neuroscience, Inc. His work in these organizations has facilitated groundbreaking research and development in the field of neuroscience and pharmacology.

Collaborations

Throughout his career, Glennon has collaborated with notable individuals in the field, including Bryan Roth and Ho Law. These partnerships have contributed to the advancement of research and innovation in mental health treatments.

Conclusion

Richard A. Glennon's innovative work in the development of serotonin receptor antagonists has significantly advanced the field of mental health treatment. His contributions continue to influence the therapeutic landscape, providing hope for those affected by mental disorders.